ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01630057
Recruitment Status : Completed
First Posted : June 28, 2012
Last Update Posted : July 14, 2014
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
An open-label, randomized, multi-centre, superiority study to assess that, in patients who respond to zonisamide added as third drug after failure of a two-drug combination therapy, the triple therapy is superior to the conversion to a double therapy including zonisamide.

Condition or disease Intervention/treatment Phase
Partial Seizures Drug: Adjunctive Zonisamide Drug: Replacement with Zonisamide Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Randomized, Multi-centre, Superiority Study to Compare, in Patients With Partial Onset Seizures, the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug
Study Start Date : September 2009
Actual Primary Completion Date : June 2011
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Seizures
Drug Information available for: Zonisamide
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Adjunctive Zonisamide
Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
Drug: Adjunctive Zonisamide
Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
Active Comparator: Replacement with Zonisamide
Patients will continue to receive zonisamide as third drug
Drug: Replacement with Zonisamide
Patients will continue to receive zonisamide as third drug



Primary Outcome Measures :
  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability in patients who respond to zonisamide added as third drug after failure of a two-drug combination therapy [ Time Frame: 13 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Patients with localization-related epilepsy, who have added a second drug to the monotherapy, haven't obtained an adequate reduction of seizure frequency with this combination and have responded to zonisamide added as third drug for at least three months.

Inclusion criteria:

  • Age ≥ 18 years;
  • Patients with non progressive localization-related epilepsy;
  • Patients who are able and willing to give written Informed Consent;
  • Current treatment with three antiepileptic drugs. The last antiepileptic drug introduced must be zonisamide;
  • 50% or greater seizure reduction* as assessed after an at least three-month maintenance period with zonisamide.

    • = seizure frequency before starting zonisamide must be documented checking case histories.

Exclusion criteria:

  • Patients contraindicated for zonisamide use (see SmPC);
  • Patients with renal or hepatic impairment;
  • Pregnant or lactating women;
  • Women of childbearing age who are not willing to use any contraceptive method with established efficacy.
  • Patients suffering from clinically significant psychiatric illness, psychological or behavioral problems which could interfere with study participation;
  • Patients with a history (within the last 12 months) of alcohol or drug abuse or dependency;
  • Patients who have been on an investigational drug or device within 30 days prior to the initiation of the present study;
  • Patients with a documented computed axial tomography (CAT) scan or magnetic resonance imaging (MRI) scan confirming the presence of a progressive neurological lesion within 12 months of the screening visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01630057


Locations
Italy
AOU Ospedali riuniti Umberto I -G.M Lancisi-G.Salesi
Ancona, Italy, 60126
AO Universitaria Consorziale Policlinico di Bari
Bari, Italy, 70124
Irccs "E. Medea"
Bosisio Parini, Italy, 23842
Struttura di Neurofisiopatologia, Universit? degli studi di Cagliari
Cagliari, Italy, 09124
IRCCS "Eugenio Medea" Polo Scientifico di Conegliano
Conegliano, Italy, 31015
AOU di Ferrara Arcispedale S. Anna
Ferrara, Italy, 44100
Presidio Ospedale "S.Antonio Abate di Gallarate"
Gallarate, Italy, 21013
UOC Neurofisiopatologia PO S. Salvatore
L'Aquila, Italy, 67100
AO della Provincia di Lodi
Lodi, Italy, 26900
IRCCS Centro neurolesi "Bonino Pulejo" di Messina
Messina, Italy, 98124
AO di Rilievo Nazionale Antonio Cardarelli
Napoli, Italy, 80131
AO Universitaria Federico II
Napoli, Italy, 80131
AO Universitaria Policlinico Paolo Giaccone dell'Universit? degli Studi di Palermo
Palermo, Italy, 90127
AO Universitaria -Pisana
Pisa, Italy, 56126
AO Regionale "San Carlo" di Potenza
Potenza, Italy, 85100
PO "Misericordia e dolce"-USL 4 di Prato
Prato, Italy, 59100
Azienda Complesso Ospedaliero San Filippo Neri
Roma, Italy, 00135
Umberto I Policlinico di Roma
Roma, Italy, 00161
Ospedale SS Giovanni e Paolo Azienda ULSS 12 Veneziana
Venezia, Italy, 30174
Sponsors and Collaborators
Eisai Inc.
Investigators
Principal Investigator: Salvatore Striano Azienda Ospedaliera Universitaria Federico II

Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT01630057     History of Changes
Other Study ID Numbers: E2090-E039-401
First Posted: June 28, 2012    Key Record Dates
Last Update Posted: July 14, 2014
Last Verified: July 2014

Additional relevant MeSH terms:
Seizures
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Zonisamide
Anticonvulsants
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs